ADC Therapeutics (ADCT) Invested Capital (2019 - 2026)

ADC Therapeutics has reported Invested Capital for 7 years, with the latest figure at $4.6 million in Q1 2026.

• Quarterly Invested Capital changed N/A year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (changed N/A YoY) and the FY2025 annual result came in at $3.0 million, changed N/A from the prior year.
• Invested Capital rose to $4.6 million in Q1 2026 per ADCT's latest filing, from $3.0 million in the prior quarter.
• Over five years, Invested Capital peaked at $426.8 million in Q4 2022 and troughed at $3.0 million in Q4 2025.
• A 4-year average of $103.1 million and a median of $120.0 million in 2022 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2023: Invested Capital retreated 1.08% in 2022, then jumped 1732.34% in 2023.
• Over 4 years, Invested Capital stood at $426.8 million in 2022, then plunged by 71.89% to $120.0 million in 2023, then tumbled by 97.5% to $3.0 million in 2025, then surged by 54.5% to $4.6 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $4.6 million, $3.0 million, and $120.0 million for Q1 2026, Q4 2025, and Q3 2023 respectively.